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Prognostic and therapeutic relevance of FLIP and
procaspase-8 overexpression in non-small cell lung
cancer
JS Riley1, R Hutchinson1, DG McArt1, N Crawford1, C Holohan1, I Paul1, S Van Schaeybroeck1, M Salto-Tellez1, PG Johnston1,
DA Fennell2, K Gately3, K O’Byrne3, R Cummins4, E Kay4, P Hamilton1, I Stasik1 and DB Longley*,1
Non-small cell lung carcinoma remains by far the leading cause of cancer-related deaths worldwide. Overexpression of FLIP,
which blocks the extrinsic apoptotic pathway by inhibiting caspase-8 activation, has been identified in various cancers. We
investigated FLIP and procaspase-8 expression in NSCLC and the effect of HDAC inhibitors on FLIP expression, activation of
caspase-8 and drug resistance in NSCLC and normal lung cell line models. Immunohistochemical analysis of cytoplasmic and
nuclear FLIP and procaspase-8 protein expression was carried out using a novel digital pathology approach. Both FLIP and
procaspase-8 were found to be significantly overexpressed in tumours, and importantly, high cytoplasmic expression of FLIP
significantly correlated with shorter overall survival. Treatment with HDAC inhibitors targeting HDAC1-3 downregulated FLIP
expression predominantly via post-transcriptional mechanisms, and this resulted in death receptor- and caspase-8-dependent
apoptosis in NSCLC cells, but not normal lung cells. In addition, HDAC inhibitors synergized with TRAIL and cisplatin in NSCLC
cells in a FLIP- and caspase-8-dependent manner. Thus, FLIP and procaspase-8 are overexpressed in NSCLC, and high
cytoplasmic FLIP expression is indicative of poor prognosis. Targeting high FLIP expression using HDAC1–3 selective inhibitors
such as entinostat to exploit high procaspase-8 expression in NSCLC has promising therapeutic potential, particularly when
used in combination with TRAIL receptor-targeted agents.
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Non-small cell lung cancer (NSCLC) is the leading cause of
cancer-relatedmortality in the world. Despite developments in
the use of molecular-targeted therapies in stratified patient
populations, chemotherapy remains the mainstay of treatment
for NSCLC, and drug resistance remains amajor challenge that
accounts for poor survival outcomes. Novel therapeutic
approaches that exploit tumour dependencies on key pathways
are urgently needed to improve patient prognosis.
Evasion of apoptosis is a hallmark of cancer and a key cause
of therapy. One of the mechanisms by which tumours evade
apoptosis is by overexpression of anti-apoptotic proteins such as
the caspase-8 inhibitor FLIP,whichblocks induction of apoptosis
mediated by death receptors such as Fas, DR4 (TRAIL-R1)
and DR5 (TRAIL-R2).1 FLIP inhibits homo-dimerization,
self-processing and activation of procaspase-8 at the
death-inducing signalling complexes (DISCs) formed following
activation of these receptors. FLIP also blocks apoptosis
induced by the DISC-related cytoplasmic caspase-8-activating
platforms TNFR1 Complex II and the Ripoptosome.2,3
There is emerging pre-clinical and clinical evidence
that histone deacetylase inhibitors (HDACi) are promising
therapeutic agents for several cancers. However, trials in
unselected patient populations in solid tumours have been
generally disappointing, highlighting the need for predictive
biomarkers to stratify responsive patient populations and
identification of rational clinical combinations of these agents
with other drugs based on pre-clinical research.4 Another
class of anti-cancer agent assessed in NSCLC are those
targeting DR4 and DR5. Both receptors were found to be
highly expressed in NSCLC,5 providing support for their
clinical assessment in this disease. Overall, clinical trials using
recombinant forms of human TRAIL (rhTRAIL) and agonistic
antibodies targeting the receptors have been disappointing
(reviewed in den Hollander et al.6). It is important to note
however, that these trials were again conducted in unselected
patient populations.
Results
FLIP and procaspase-8 expression in NSCLC. We
previously reported that procaspase-8 was overexpressed
in 85% of a small series (n¼ 20) of NSCLC tumours of mixed
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histology.7 Moreover, FLIP was overexpressed in all tumours
that overexpressed procaspase-8. To assess the levels of
procaspase-8 and FLIP expression in a larger NSCLC
patient cohort, we generated a tissue microarray (TMA) of
184 samples, comprising three tumour cores and three cores
of adjacent normal stroma for each patient. The clinicopatho-
logical details of the patient cohort are presented in Table 1.
As described in the materials and methods, FLIP and
procaspase-8 expression were assessed by immunohisto-
chemistry and scored using a novel automated image analysis
technique, in which expression in the nuclei and cytoplasm
were individually scored from digitally captured images of
each core (Figures 1a and b and Supplementary Figure 1A).
Both proteins could be detected in the cytoplasm and nuclei
and were scored separately for each of these cellular
compartments. Expression of FLIP and procaspase-8 were
significantly higher in the cytoplasm than the nucleus in both
normal and tumour samples (Po0.0001; Figure 1c). Notably,
FLIP and procaspase-8 were expressed at significantly higher
levels in tumour tissues than in the stroma (Po0.0001;
Figure 1c). Squamous cell carcinomas had significantly higher
cytoplasmic FLIP expression (Po0.05) than adenocarcinomas,
although overall, the patterns of FLIP and procaspase-8
expression in squamous and adenocarcinomas were very
similar (Supplementary Figure 1B). Also in agreement with
our previous study, there were significant correlations
between FLIP and procaspase-8 expression in both the
nuclear and cytoplasmic compartments (Figure 1d). There
were no correlations between procaspase-8 and FLIP
expression levels and gender, smoking history or tumour
grade (data not shown).
Comparison of Kaplan–Meier curves for low (less than the
median) versus high (greater than the median) expression
revealed no significant correlation within 5 years of follow-up
for nuclear FLIP, nuclear procaspase-8 and cytoplasmic
procaspase-8, however there was a significant correlation
(P¼ 0.032) for high cytoplasmic FLIP expression being
associated with shorter OS (Figure 1e; HR¼ 1.59). The
correlation of high cytoplasmic FLIP with poor prognosis was
also apparent in both adenocarcinoma and squamous
histological sub-types and was more marked in the squamous
tumours, although these correlations failed to reach
significance in these smaller sub-groups (adenocarcinoma:
P¼ 0.15, HR¼ 1.54; squamous: P¼ 0.07, HR¼ 1.98;
Supplementary Figure 2).
HDAC inhibitors induce FLIP downregulation and cell
death in NSCLC cells. The high frequency of procaspase-8
and FLIP overexpression and the correlation of high
cytoplasmic FLIP expression with poor prognosis suggested
that a significant proportion of NSCLCs may be vulnerable to
procaspase-8-mediated apoptosis if the inhibitory effects of
FLIP overexpresion could be therapeutically overcome.
Western blot analyses demonstrated that knockdown of both
major FLIP splice forms (FLIPS and FLIPL) in the H460 and
A549 NSCLC cell line models was sufficient to induce PARP
cleavage, indicative of apoptosis (Figure 2a), showing that
these NSCLC cell lines are dependent on FLIP to maintain
viability. Vorinostat and panobinostat are pan-HDAC inhibi-
tors that have been identified by us and others as modulators
of FLIP expression in several pre-clinical cancer models.8–10
Treatment with either of these HDAC inhibitors for 24 h
resulted in downregulation of FLIP protein expression in
NSCLC cells at clinically achievable doses (Figure 2b and
Supplementary Figure 3A). Moreover, significant downregu-
lation of both major FLIP splice forms was observable 6 h
after vorinostat treatment. FLIP downregulation in response
to both pan-HDAC inhibitors correlated with caspase-3
activation and PARP cleavage at 24 h (Figure 2b and
Supplementary Figure 3A–C). The only other major anti-
apoptotic protein downregulated in response to HDAC
inhibitors was XIAP, which was significantly downregulated
after 24 h in both cell lines (Supplementary Figure 3B);
interestingly, vorinostat synergized with the XIAP antagonist
Birinapant in H460 and A549 cells (Supplementary
Figure 4D).
Vorinostat potently suppressed FLIP expression for 72 h
and decreased procaspase-8 expression (an indication of
processing and activation) was observed (Figure 2c). In a
normal lung fibroblast cell line, 34LU, FLIPS expression was
significantly lower (Figure 2d) and FLIP was only down-
regulated at the highest concentrations of HDAC inhibitor
Table 1 Clinicopathological characteristics of NSCLC patients and their
tumours used in this study
Characteristics N (%)
Total 184 (100%)
Median age (range) 66.1 (41–86)
Gender
Male 112 (62.7%)
Female 72 (37.3%)
Smoking history
Former/current 171 (93.5%)
Never 13 (6.5%)
Histology
Adenocarcinoma 83 (43.8%)
Squamous cell carcinoma 83 (46.3%)
Large cell carcinoma 4 (2.5%)
Pleomorphic 7 (3.5%)
Mixed 7 (3.5%)
pTNM stage
I 99 (54.2%)
II 43 (23.9%)
III 42 (21.9%)
Tumour size
r2 cm 20 (11.4%)
42–3 cm 31 (16.9%)
43–5 cm 89 (46.3%)
45–7 cm 24 (14.4%)
47 cm 20 (10.9%)
Type of resection
Lobectomy 135 (72.1%)
Bilobectomy 17 (10.4%)
Pneumonectomy 32 (17.4%)
Tumour grade
G1 11 (6.5%)
G2 110 (58.7%)
G3 63 (34.8%)
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used, and then only after 24 h (Figure 2e and Supplementary
Figure 3D). Compared with the NSCLC models, vorinostat
and panobinostat induced significantly less apoptosis in 34LU
cells as determined by PARP cleavage (Figure 2e and
Supplementary Figure 3D) and flow cytometry (Figure 2f).
Vorinostat downregulated FLIP mRNA levels byB50% 6h
post treatment in each cell line (Supplementary Figure 4A). In
H460 cells, FLIP mRNA expression recovered to control
levels by 24h; whereas in A549 cells, FLIP mRNA expression
remained downregulated. However, in both cell lines, the
downregulation of FLIP mRNA expression was insufficient to
account for the downregulation of FLIP protein expression,
particularly at later timepoints, suggesting that vorinostat
predominantly suppresses FLIP protein expression at a post-
transcriptional level in these models. FLIP is a known
caspase-8 substrate; therefore we investigated whether FLIP
downregulation post-HDAC inhibitor treatment was due to
activation of caspases. Notably, FLIP downregulation in
response to vorinostat was unaffected by co-treatment with
the pan-caspase inhibitor z-VAD-fmk (Supplementary
Figure 4B). However, HDAC inhibitor-induced downregulation
of FLIP was blocked in cells pre-treated with the proteasome
inhibitor MG132 (Supplementary Figure 4C), indicating that
the ubiquitin-proteasome pathway is involved in HDAC
inhibitor-mediated FLIP downregulation in NSCLC.
Vorinostat-induced cell death is dependent on the
extrinsic apoptotic pathway. In both H460 and A549 cells,
downregulation of procaspase-8 rescued the cell death
phenotype induced by vorinostat (Figure 3a), demonstrating
that the apoptosis induced by this agent is dependent on
activation of caspase-8. Notably, vorinostat-resistant 34LU
fibroblasts expressed significantly lower levels of procas-
pase-8 than the NSCLC cell lines (Figure 2d). Treatment
of FLIP-overexpressing cells with vorinostat resulted in
significantly less apoptosis compared with the empty vector
(EV) control line (Figure 3b). Collectively, these data show
that vorinostat-induced cell death is critically dependent on
FLIP downregulation and caspase-8 activation. Furthermore,
we found that vorinostat-induced apoptosis after 24 and 48 h
was significantly attenuated in H460 and A549 cells in which
either DR4 or DR5 (but not Fas) was downregulated
Nuclear FLIP
0 20 40 60
0
20
40
60
80
100 Low
High
p=0.633
HR=1.1 (0.75-1.62)
Overall Survival (months)
Pe
rc
en
t s
ur
vi
va
l
Cytoplasmic FLIP
0 20 40 60
0
20
40
60
80
100 Low
High
p=0.0321
HR=1.59 (1.04-2.30)
Overall Survival (months)
Pe
rc
en
t s
ur
vi
va
l
Nuclear Caspase-8
0 20 40 60
0
20
40
60
80
100 Low
High
p=0.9875
HR=1.00 (0.68-1.46)
Overall Survival (months)
Pe
rc
en
t s
ur
vi
va
l
Cytoplasmic Caspase-8
0 20 40 60
0
20
40
60
80
100 Low
High
p=0.6102
HR=1.10 (0.76-1.61)
Overall Survival (months)
Pe
rc
en
t s
ur
vi
va
l
Nuclear FLIP
Str
om
al
Tu
mo
ral
0
100
200
300
400 P<0.0001
Ex
pr
es
si
on
 L
ev
el
s
Cytoplasmic FLIP
Str
om
al
Tu
mo
ral
0
100
200
300
400 P<0.0001
Ex
pr
es
si
on
 L
ev
el
s
Nuclear Caspase-8
Str
om
al
Tu
mo
ral
0
100
200
300
400 P<0.0001
Ex
pr
es
si
on
 L
ev
el
s
Cytoplasmic Caspase-8
Str
om
al
Tu
mo
ral
0
100
200
300
400 P<0.0001
Ex
pr
es
si
on
 L
ev
el
s
Tumor
Stroma
Background
Nucleus
detection
Nucleus
quantification
Cell boundary
identification
Classification of
cyt expression
FL
IP
FL
IP
Caspase-8 Caspase-8
PC= 0.175; p=0.035PC= 0.252; p=0.002
Nucleus Cytoplasm
Segmentation of nuc
and cyt compartments 
Figure 1 FLIP and procaspase-8 expression in tumour samples; clinical correlates. (a) Automated tumour identification (‘region recognition module’) of lung
adenocarcinoma tissue stained with FLIP antibody. (b) The ‘cellular detection module’: nucleus detection, nucleus quantification, cell boundary identification,
segmentation of nucleus and cytosolic compartments and classification of cytosolic expression. (c) Absolute expression of FLIP and procaspase-8 in nuclei and
cytoplasm across all patients. Significance determined by Mann–Whitney non-parametric, two-tailed t-test. (d) Correlations between tumoral expression of FLIP and
procaspase-8 in nuclei (left) and cytoplasm (right), as determined using Pearson’s correlation. (e) Correlations of disease-free survival with the level of nuclear and
cytoplasmic FLIP or procaspase-8 expression in tumour tissue across all patients. Statistical significance of Kaplan–Meier curves was determined by the log-rank
(Mantel–Cox) test
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(Figure 3c and data not shown), providing further evidence
for the involvement of the extrinsic apoptotic pathway in
mediating vorinostat-induced apoptosis.
Loss of expression of BAK has been observed in 34–47% of
surgically resected NSCLC tumours, and loss of BAX
expression in 42–59%.11 As these proteins are potent
apoptosis activators, this downregulation could potentially
mediate profound chemo-resistance. We assessed whether
BAX/BAK-deficient tumours were resistant to treatment with
HDAC inhibitors by analysing two H460 daughter cell lines
stably expressing shRNAs targeting BAX and BAK
(Figure 3d). Notably, the levels of apoptosis induced by
vorinostat in the BAX/BAK-deficient cells were comparable to
those in a control cell line expressing non-targeting shRNA
(Figures 3e and f).
Vorinostat potentiates the effect of cisplatin in NSCLC
cells. Cisplatin is a DNA-damaging agent used as first-line
treatment for patients with stage IV NSCLC, although only
B20% of patients respond.12,13 Co-treatment with vorinostat
and cisplatin increased PARP cleavage and processing of
procaspase-3 into its active form compared with treatment
with each agent individually (Figure 4a). In addition,
vorinostat and cisplatin co-treatment dramatically reduced
long-term clonogenic survival compared with either of the
drugs alone in both cell lines (Figure 4b and Supplementary
Figure 5C), and short-term cell viability assays clearly
demonstrated strong synergy between the two drugs, with
combination indices (CIs) for nearly all dose combinations
o1, with many of them falling between 0.3 and 0.7
(Figure 4c). Mechanistically, FLIP overexpression reduced
PARP cleavage and processing of procaspase-8 to its p18
form in response to combined cisplatin/vorinostat co-treat-
ment (Figure 4d), whereas RNAi-mediated procaspase-8
depletion blocked the additional apoptosis induced when
vorinostat was co-administered with cisplatin (Figure 4e).
Thus, the synergy between cisplatin and vorinostat is
dependent on FLIP downregulation and caspase-8 activa-
tion; although it should be noted that neither FLIP over-
expression nor procaspase-8 depletion inhibited the
apoptosis induced by cisplatin alone (Figures 4d and e).
Vorinostat synergizes with TRAIL in NSCLC cells. As
FLIP is a potent inhibitor of TRAIL-mediated apoptosis, we
postulated that pre-treating cells with HDAC inhibitors to
downregulate FLIP would overcome resistance to TRAIL in
NSCLC. Indeed, co-treatment of H460 and A549 cells with
vorinostat and TRAIL resulted in significant apoptosis
induction as assessed by PARP cleavage and caspase-3
processing (Figure 5a). This combination also synergistically
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Figure 2 HDACi induce FLIP downregulation and apoptosis in NSCLC cell lines. (a) Western blot analysis of FLIP expression and PARP cleavage in H460 and A549 cells
transfected with FLIP-targeted siRNA (FT) for 24 h. (b) Western blot analysis of FLIP expression and PARP cleavage in H460 and A549 cells treated with the indicated doses of
vorinostat for 6 or 24 h. (c) Western blot analysis of FLIP and procaspase-8 expression and PARP cleavage in H460 and A549 cells treated with 5mM vorinostat for the indicated
timepoints. (d) Western blot analysis of basal FLIP, procaspase-8 and FADD expression in H460 and A549 NSCLC cells and 34LU normal lung fibroblasts. (e) Western blot
analysis of FLIP and procaspase-8 expression and PARP cleavage in 34LU cells treated with vorinostat for 24 h. (f) Flow cytometric analysis of apoptosis (sub-G1 population) in
H460, A549 and 34LU cells treated with vorinostat for the indicated times. Significant differences were determined by Student’s t-test: *Po0.05; **Po0.01; ***Po0.001
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decreased long-term clonogenic survival (Figure 5b and
Supplementary Figure 5C) and short-term cell viability as
determined by the CI method (Figure 5c). Furthermore,
H460 cells that have acquired resistance to cisplatin14
still undergo apoptosis in response to FLIP downregulation
and vorinostat (Supplementary Figure 5A–C). Moreover,
these cisplatin-resistant cells are as sensitive as the parental
cells to combined treatment with vorinostat and TRAIL;
however vorinostat did not reverse their acquired resistance
to cisplatin (Supplementary Figure 6D). Mechanistically,
overexpression of FLIP protected cells from apoptosis
induced by TRAIL alone, vorinostat alone and the combina-
tion as assessed by PARP cleavage and processing of
procaspase-8 to its p18 subunit (Figure 5d). Similarly,
RNAi-mediated procaspase-8 depletion significantly pro-
tected cells from apoptosis induced by TRAIL and vorinostat
(Figure 5e).
Inhibition of HDACs 1, 2 and 3 is required for FLIP
downregulation. HDACs 1, 2 and 3 were found to be more
highly expressed in the NSCLC cell lines than in the normal
fibroblasts, whereas HDAC6 (detected as two bands) was
higher in the fibroblasts (Figure 6a). While vorinostat and
panobinostat inhibit a broad spectrum of HDACs,15 HDAC
inhibitors with greater specificity have been developed, such
as entinostat (MS-275), which inhibits HDACs 1, 2 and 3, but
not HDAC6, and ACY-775, which is highly selective for
HDAC6 but has no activity against HDACs 1–3.16,17 Notably,
entinostat, but not ACY-775, induced significant downregula-
tion of FLIP protein expression in H460 and A549 cells
(Figure 6b), suggesting that HDACs 1–3, but not HDAC6, are
important for regulating FLIP expression in NSCLC. Entino-
stat also downregulated FLIP expression in 34LU cells
(Figure 6c). Co-treatment with entinostat enhanced cispla-
tin-induced apoptosis in A549 cells (albeit to a lesser extent
than vorinostat), but not H460 cells as determined by PARP
cleavage and caspase-3 activation (Figure 6c) and flow
cytometry (Figure 6d). However, similar to vorinostat,
entinostat synergistically enhanced TRAIL-induced apoptosis
in both NSCLC cell lines (Figures 6c and d). Of note,
entinostat was significantly less toxic than vorinostat to 34LU
cells, either as a single agent or in combination with
TRAIL (Figures 6c and d); although similar to vorinostat, it
enhanced cisplatin-induced apoptosis in the normal lung
cells (Figures 6c and d). Like vorinostat, the effects of
entinostat on TRAIL- and cisplatin-induced apoptosis
were caspase-8-dependent (Figure 6e), consistent with a
FLIP-dependent mode of cell death induction.
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Figure 3 HDACi-induced apoptosis of NSCLC cells is dependent on the extrinsic apoptotic pathway. (a) Flow cytometric analysis of apoptosis (sub-G1 population) in H460
and A549 cells treated with 1 or 5 mM vorinostat for 24 or 48 h. Cells were transfected with 20 nM procaspase-8-targeted (siCaspase-8) or control (SC) siRNA for 48 h before
vorinostat treatment. Efficiency of procaspase-8 depletion is shown by immunoblot. Significant differences were determined using Student’s t-test. (b) Flow cytometric analysis
of apoptosis (sub-G1 population) in control (EV) and FLIPs overexpressing H460 cells treated with 2.5mM vorinostat for 48 h. FLIP overexpression was determined by western
blotting, and significance was determined using Student’s t-test. (c) Death receptors DR4, DR5 or Fas were silenced for 48 h with 20 nM specific siRNA, following which the
cells were treated with 5mM vorinostat for a further 24 h. Sub-G1 populations were analysed by flow cytometry. Significance was determined by Student’s t-test. (d) Western
blot analysis of BAX and BAK in two H460 cell lines stably expressing shRNAs targeting BAX and BAK (shBAX/BAK) or non-targeting (shNT/NT) shRNAs. (e) Sub-G1 analysis
of apoptosis in shBAX/BAK cells treated with 5mM vorinostat for 48 h. (f) Western blot analysis of FLIP expression and PARP cleavage in shBAX/BAK cells treated for 48 h
with 5 mM vorinostat. Significant differences were determined by Student’s t-test: *Po0.05; **Po0.01; ***Po0.001
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Discussion
NSCLC is particularly resistant to chemotherapy. Mutations
or alterations in expression of proteins regulating apoptosis
often arise during carcinogenesis or during treatment; this
can be a major cause of clinical drug resistance, therefore
therapies that specifically target these proteins are being
actively sought.18–21 One of these anti-apoptotic proteins is
FLIP, which is overexpressed in several cancer types and
has been associated with drug resistance and poor
prognosis,1 but for which there are currently no direct
inhibitors.
In this study, we used a novel automated scoring technique
to assess nuclear and cytoplasmic expression of FLIP and
procaspase-8 in tumour and adjacent stroma tissue from a
cohort of 184 stage I–III patients with mixed histology NSCLC.
Unlike small cell lung cancer in which procaspase-8 expres-
sion is frequently downregulated or deleted,22 NSCLC
tumours expressed significantly higher levels of procaspase-
8 compared with surrounding stromal tissue. FLIP was also
frequently overexpressed, and we observed positive correla-
tions between the levels of FLIP and procaspase-8 expres-
sion within the tumour tissues. Notably, we found a significant
correlation between high cytoplasmic FLIP expression and
poor OS that was not apparent for nuclear FLIP expression,
consistent with the primary function of FLIP as a caspase-8
inhibitor being cytoplasmic.1 Further analyses in an expanded
patient cohort are now required to assess whether high
cytoplasmic FLIP expression as assessed using this auto-
mated scoring approach has clinical utility as a biomarker of
poor prognosis in NSCLC.
We have previously shown that RNAi- and antisense-
mediated FLIP downregulation induces apoptosis in NSCLC
cell lines in vitro and in vivo7,23 and that the sensitivity of
NSCLC cells to FLIP downregulation is dependent on their
elevated expression of procapase-8.7 Thus, FLIP represents
an attractive therapeutic target in this disease. There have
been a number of in vitro studies in a range of malignancies
showing FLIP downregulation in response to HDAC inhibi-
tors.8,10,24–27 Although FLIP downregulation following treat-
ment with pan-HDAC inhibitors has been documented, it is not
known which particular HDACs are responsible for mediating
this effect in different tumour types. Our results show that
inhibition of HDAC1, 2 and/or 3, but not HDAC6, is necessary
for efficient FLIP downregulation in NSCLC. This is interesting
given the predominantly (but not exclusively) nuclear expres-
sion of these HDACs.28
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HDAC inhibitors are a novel class of agents with a variety
of chemical structures that are thought to exert their anti-
cancer effects by epigenetically altering gene expression.29
However, it is becoming increasingly apparent that effects on
the epigenome may not be the only (or indeed primary) anti-
cancer mechanism of action of HDAC inhibitors, which in turn
has implications for how these drugs should be rationally
combined with other agents to maximize their therapeutic
potential.30,31 There are many HDAC inhibitors at various
stages of clinical development and, to date, vorinostat and
Istodax/romidepsin have been approved for use in cutaneous
T-cell lymphoma.32–35 The benzamide entinostat (MS-275/
SNDX-275) is an HDAC1/2/3-selective inhibitor that has been
in numerous clinical trials, including several in NSCLC most
often combined with the demethylatng agent azacitidine.36
Entinostat is generally well tolerated and has a significantly
longer plasma half-life in man than the hydroxamic acid HDAC
inhibitors such as vorinostat and panobinostat.36
Cisplatin, in combination with pemetrexed, is currently
the first-line standard-of-care chemotherapy for patients
with NSCLC.12,13 Notably, co-treatment with vorinostat,
synergistically enhanced cisplatin-induced apoptosis in
NSCLC cells, and this increased apoptosis was atte-
nuated by FLIP overexpression or caspase-8 silencing.
There is already clinical evidence for combining platinum
drugs with HDAC inhibitors: a phase II trial of carboplatin/
paclitaxel with or without vorinostat in NSCLC reported
significantly improved response rates and a trend towards
improved survival for the vorinostat arm.37 This suggests that
there is a cohort of NSCLC patients who will benefit
from addition of an HDAC inhibitor to platinum-based
chemotherapy.
TRAIL and agonistic TRAIL receptor antibodies are currently
being assessed for use as anti-cancer agents.38 Although well
tolerated, the results of clinical trials in solid tumours have been
disappointing so far; however, it is important to note that all
trials to date have been conducted in unselected patient
populations due to lack of predictive biomarkers for this class of
agent.6We found that co-treatment with vorinostat or entinostat
sensitized NSCLC cells to TRAIL in a FLIP- and caspase-8-
dependent manner. This result is in agreement with other
studies; for example, Frew et al.24 reported that vorinostat
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acted synergistically with MDS-1 (an anti-TRAIL-R agonistic
monoclonal antibody) in a panel of cancer cell lines and
caused tumour regression in a mouse breast cancer model.
We have previously demonstrated increased TRAIL sensitivity
following treatment with vorinostat in mesothelioma and
colorectal cancer models, which was also FLIP- and
caspase-8-dependent.8,10 We postulate that resistance to
TRAIL agonists in NSCLC is mediated by high levels of
cytoplasmic FLIP expression and may therefore be overcome
by co-treatment with HDAC inhibitors. Notably, unlike addition
of cisplatin, the addition of TRAIL to vorinostat did not further
increase apoptosis in normal lung fibroblasts, suggesting that
there may be a wider therapeutic window for this combination.
In this regard, entinostat was as effective as vorinostat at
enhancing TRAIL-induced apoptosis in the NSCLC models,
but this combination had no effect at all on the normal lung
cells. Moreover, entinostat alone was less toxic to the normal
cells than vorinostat, suggesting that this more selective
HDAC inhibitor would be the better tolerated, in agreement
with clinical observations.36
To maximize the therapeutic impact of HDAC inhibitors in
NSCLC, predictive biomarkers for their targeted use in
selected patient populations are urgently needed. TRAIL
receptor-targeted therapeutics also currently lack predictive
biomarkers of response. Our data suggest that tumours with
high cytoplasmic FLIP and/or procaspase-8 expression may
be particularly responsive to HDAC inhibitor-based combina-
tion therapies, in particular combinations with TRAIL receptor-
targeted agents. To begin to assess this, automated scoring
techniques of the type described herein could be used to
retrospectively assess whether cytoplasmic FLIP and/or
procaspase-8 expression in tumours correlates with sensitivity
or resistance in clinical trials of HDAC inhibitors37 and
TRAIL-targeted therapeutics (reviewed in den Hollander
et al.6) in NSCLC.
Materials and Methods
Patients. This is a retrospective study of patients who underwent curative-intent
surgical resection of a primary tumour at St. James’s Hospital, Dublin between
February 2001 and February 2005. A cohort of 184 stage I–III NSCLC patients,
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staged according to the International System of Staging for Lung Cancer, was
randomly selected. Information on baseline demographics, clinicopathological
characteristics and surgical approach was collected after review of clinical notes
and histopathology reports. Outcome data, including peri-operative mortality and
long-term survival, was updated prospectively. Patients’ characteristics are
detailed in Table 1. This study was approved by the St. James’s Hospital Ethics
Committee.
Generation and staining of TMAs. A 4-mm section was cut from
formalin-fixed, paraffin-embedded tissue blocks from the 184 patients. This section
was stained with hematoxylin-eosin for light microscopic examination by a
pathologist (EK) to confirm areas of tumour. Three to four areas of tumour were
marked on each section. Three cores, each 2 mm in diameter, were removed
from each patient ‘donor’ block and inserted into a ‘recipient’ TMA block. A series
of sections were cut from each TMA block, the first and last sections being
stained with hematoxylin-eosin with tumour content confirmed by a pathologist.
TMAs were assessed for FLIP and procaspase-8 expression as previously
reported.39
TMA machine scoring and analysis. Slides were scanned using an
Aperio ScanScope CS (Aperio, San Diego, CA, USA) at a resolution of  40
using the objective  40/0.75 Plan Apo with a doubler and loaded onto the local
drive for storage. The digitized TMA slides were imported into Definiens Tissue
Studio, v2.1 (Definiens AG, Munich) for image analysis. The digital images were
‘dearrayed’ within Tissue Studio to generate individual core images with registered
coordinates matching the original TMA layout. Twelve of the dearrayed cores were
used in a training set to define a completely novel cytonuclear algorithm for the
quantitative analysis of FLIP and procaspase-8 expression. An automated region
recognition module was applied to the training set to initially identify and
distinguish regions of tumour, stroma and background at a magnification of  20
(Figure 1a). Nuclear detection was subsequently carried out independently on both
tumour and stroma. Thresholds were identified to distinguish between positive and
negative nuclei expression for each protein using an image object information
table. In addition, a nuclei filter was used to remove over-segmented nuclei. Cell
simulation based on growing boundaries around the nuclei was used to model and
identify the cytoplasmic compartment (Figure 1b). This allowed automatic
identification of cytonuclear compartments, within which protein expression
density was then calculated. Results were reviewed by an experienced pathologist
(MS-T). Nuclear and cytoplasmic expression of FLIP and procaspase-8 were
objectively measured automatically across all TMA cores. Statistical analyses were
performed using GraphPad Prism version 5. Comparisons between matched
tumour and stroma were analysed using Mann–Whitney non-parametric t-test.
Correlations were assessed using Pearson’s correlation coefficient method.
Disease-free survival between the groups was compared using Kaplan–Meier
method and log-rank (Mantel–Cox) analysis.
Cell lines and cell culture. H460, A549 and 34LU cell lines were obtained
from ATCC (Teddington, UK) and maintained as previously described.7 All cell
lines were regularly screened for presence of mycoplasma using the MycoAlert
Mycoplasma Detection Kit (Lonza, Basel, Switzerland). Cisplatin-resistant and
Bax/Bak-shRNA H460 cells15,18 were described previously.
Generation of stable overexpressing cell lines. FLIPS coding region
was PCR amplified and ligated into the pBABEpuro vector, according to standard
protocols. Phoenix GP cells (Nolan Lab, Stanford University) were co-transfected
with 4 mg of the pBABEpuro vector and VSVG coat-protein plasmid. After 24 h, the
virus-containing media was removed, filtered and added to H460 cells; stable
transfectants were selected in 1 mg/ml puromycin (Sigma).
Reagents. Vorinostat (SAHA), panobinostat (LBH-589), entinostat (MS-275)
and birinapant (TL32711) were purchased from Selleck Chemicals (Newmarket,
UK); ACY-775 was obtained from Acetylon Pharmaceuticals, Boston, MA, USA;
cisplatin (Hospira, UK) was obtained from the Belfast City Hospital Pharmacy.
Recombinant human TRAIL and z-VAD-fmk were purchased from Calbiochem
(Watford, UK) and MG132 (Z-Leu-Leu-Leu-Leu-al) from Sigma-Aldrich (Gillingham,
Dorset, UK).
Western blotting and antibodies. Cells were harvested and lysed in
RIPA buffer. Western blotting was carried out as previously described.8 FLIP
(NF6) and caspase-8 (12F5) antibodies were obtained from Alexis Biochemicals
(San Diego, CA, USA), PARP antibody was from eBioscience (San Diego, CA,
USA), b-actin, HDAC3 and HDAC6 were from Sigma-Aldrich. Antibodies for
acetylated alpha-tubulin, acetylated histone H4, caspase-3, XIAP, cIAP1, BAX,
BAK, BCL-2, MCL-1, BID, HDAC1 and HDAC2 were from Cell Signaling
Technology (Hitchin, UK).
Clonogenic assays. H460 and A549 cells were seeded at 500 cells per well
on six-well plates. The following day, cells were treated as required. At the end of
treatment, the media was replaced with fresh medium and allowed to grow until
colonies formed. Cells were fixed in ice-cold methanol, stained with crystal violet
solution and colonies counted.
MTT cell viability assays. Cells (4000) were seeded per well on 96-well
plates. After 24 h, cells were treated for the appropriate time, after which MTT
(0.5 mg/ml) was added to each well and the cells incubated at 37 1C for a further
2 h. The culture medium was removed and formazan crystals reabsorbed in 200ml
DMSO. Cell viability was determined by reading each well at 570 nm on a
microplate reader (Molecular Devices, Wokingham, UK).
siRNA transfections. Scrambled control (SC) siRNA, FLIP, caspase-8,
DR4, DR5 and Fas siRNAs were obtained from Dharmacon (Chicago, IL, USA) as
previously described.40 siRNA transfections were carried out using OligofectAMINE
(Invitrogen), according to the manufacturer’s instructions.
Quantitative PCR (Q-PCR). RNA was isolated from harvested cells using
GeneJET RNA purification columns (Thermo Scientific, St. Leon-Rot, Germany)
and reverse transcribed using Moloney murine leukaemia virus-based reverse
transcriptase kit (Invitrogen). Q-PCR analysis of FLIP gene expression was
performed using Real Time Ready probes and the Roche LightCycler 480 system
(Roche Diagnostics, Burgess Hill, UK).
Flow cytometry. Cell death was determined as previously described.8
Harvested cells were stained with propidium iodide (Sigma-Aldrich) and
their DNA content evaluated on a BD FACS Calibur flow cytometer
(BD, Oxford, UK).
Caspase activity assays. A volume of 25ml Caspase-8 or caspase-3/7-GLO
reagent (Promega, Southampton, UK) were added to 1–10mg of protein lysate
and incubated for 1 h at room temperature. Luciferase activity was determined
using a luminometer.
Statistics for in vitro analyses. Student’s t-test and two-way analysis of
variance (ANOVA) were used for statistical analysis; * denotes Po0.05;
** denotes Po0.01; *** denotes Po0.001. Drug interactions were determined
by calculating CI values calculated from isobolograms generated using the
CalcuSyn software. A CI value of 0.85–0.9 is slightly synergistic, 0.7–0.85
is moderately synergistic, 0.3–0.7 is synergistic and 0.1–0.3 is strongly
synergistic.41
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